
The Role of Inflammation and Risks of Stroke in Psoriatic Arthritis
Experts now believe that psoriatic arthritis should be considered a risk factor for cardiovascular diseases, including stroke.
Inflammation is a known risk factor for heart disease, and patients with inflammatory arthritis, such as rheumatoid arthritis, lupus, and psoriatic arthritis, have more cardiac events. Psoriatic arthritis patients have higher rates of atherosclerosis than the general population and those who develop it have more inflammation overall. Experts now believe that
Inflammation, as defined by abnormally high levels of inflammatory markers, has been associated with an increased risk of stroke.
Severe psoriatic arthritis patients have a higher risk of developing both metabolic syndrome and insulin resistance, which increases their risk for myocardial infarction and stroke. Patients who develop psoriasis and psoriatic arthritis later in life and those who progress from skin involvement to psoriatic arthritis appear to have high rates of metabolic syndrome and insulin resistance. The chronic inflammation of psoriatic arthritis may drive the development of these conditions.
Psoriatic arthritis patients are at increased risk of developing cardiovascular diseases, including stroke, according to a review published in the April 25, 2016 issue of
All of the studies showed a significantly increased risk of cardiovascular disease in psoriatic arthritis patients, including a 22 percent increased risk of cerebrovascular disease conditions, such as stroke, as compared to the general population.
A significant proportion of patients with psoriatic disease are underdiagnosed and undertreated for traditional cardiovascular risk factors. New
Inflammation and Stroke
Various conditions that activate the immune system and an inflammatory cascade may also increase the risk of stroke. The risk of ischemic stroke is associated with systemic inflammation and inflammatory biomarkers, suggesting a causal relationship, state the authors of a review published in the Sept. 12 online issue of
The review, led by Mitchell S. Elkind, a vascular neurologist and epidemiologist at Columbia University and chairman of the American Stroke Association Advisory Committee, examines the effects of the immune system as a whole on the epidemiology of stroke and the associations between specific inflammatory states, biomarkers of inflammation, and the risk of incident and recurrent ischemic stroke.
Dr. Elkind writes that acute infections activate the inflammatory cascade, which might increase the subsequent risk of stroke, and that chronic infections have been associated with an increased risk of stroke.
Inflammation, the risk of stroke and biomarkers
Some inflammatory cytokines, which are drug targets in rheumatologic diseases, including ILâ6, ILâ1β, tumor necrosis factor (TNF), complement proteins, CRP, serum amyloid Aâ1 protein, coagulation proteins and fibrinogen, have chronic effects that might contribute to the formation and maturation of atherosclerotic plaques. Inflammation is likely an important contributor to atherosclerosis, plaque rupture, platelet aggregation and intravascular thrombosis, which all increase the risk of stroke. Evidence shows that the risk of stroke is increased by both acute and chronic inflammation.
CRP is the most studied of the inflammatory markers, with several large epidemiological studies associating higher circulating levels of high sensitivity CRP (hs CRP) with an increased risk of vascular events independent of traditional vascular risk factors, according to a 2002 study published in the
ILâ6 is the main driver of CRP production in the liver, and evidence suggests that this cytokine mediates atherogenesis related to classical risk factors, such as aging, hypertension, smoking and obesity, according to an article in the 2009 issue of
LpâPLA2 is a leukocyte-derived enzyme that is released in response to inflammation. It is thought to directly propagate atherogenesis by, in part, proinflammatory downstream signaling effects. It is unclear whether LpâPLA2 could be a therapeutic target, they wrote.
Prevention and Treatment of Inflammation
Lifestyle changes can help reduce inflammation and, in turn, reduce the risk of stroke. Prospective studies show that weight loss interventions lead to reductions in serum concentrations of CRP, ILâ6, and TNF. A Mediterranean diet that is rich in polyunsaturated fatty acids, fruits, vegetables and whole grains, and includes a moderate intake of alcohol and a low intake of processed and red meat has been associated with low levels of inflammation. However, a Western diet that is rich in red meat, simple carbohydrates, high-fat dairy products, and hydrogenated fats has been associated with increased levels of inflammatory markers, including CRP and ILâ6.
Statins, now used for the primary and secondary prevention of stroke, especially for those at moderate to high risk, are thought to have both lipid-lowering and anti-inflammatory effects. “Evidence is building that the anti-inflammatory effects result from their ability to interrupt isoprenoid biosynthesis and improve endothelial function, thereby lowering levels of CRP, ILâ1, ILâ6 and other inflammatory markers,” the authors of the article in
References:
- Polachek A, et al.
Risk of cardiovascular morbidity in patients with psoriatic arthritis: A meta-analysis of observational studies Arthritis Care Res (Hoboken). 2016 Apr 25. doi: 10.1002/acr.22926 - Esenwa C, et al.
Inflammatory risk factors, biomarkers and associated therapy in ischaemic stroke Nature Reviews Neurology 12, 594–604 (2016) doi:10.1038/nrneurol.2016.125 Published online 12 September 2016 - Paul M. Ridker, M.D., Nader Rifai, Ph.D., et. al.
"Comparison of C-Reactive Protein and Low-Density Lipoprotein Cholesterol Levels in the Prediction of First Cardiovascular Events," New England Journal of Medicine. November 14, 2002. DOI: 10.1056/NEJMoa021993 - Harald Schuett; Maren Luchtefeld, et. al.
"How much is too much? Interleukin-6 and its signalling in atherosclerosis," Thrombosis and Haemostasis. August 2009. DOI: http://dx.doi.org/10.1160/TH09-05-0297 - Laura C. Coates, Arthur Kavanaugh, et. al.
"Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis," Arthritis & Rheumatology. Published online March 23, 2016. DOI: 10.1002/art.39573




